proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 8, 2013, Pages 1464-1473

  Rodriguez J A ^a   Sobrino, T ^b   Orbe, J ^a   Purroy, A ^a   Martinez Vila E ^c   Castillo, J ^b   Paramo J A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Biological markers; Inflammation; Matrix metalloproteinases; Stroke; Tumor necrosis factor alpha

Indexed keywords

FIBRONECTIN; INTERLEUKIN 6; MESSENGER RNA; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN DAMAGE; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN SIZE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MENTAL FUNCTION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANKIN SCALE;

BIOLOGICAL MARKERS; INFLAMMATION; MATRIX METALLOPROTEINASES; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 10; MIDDLE AGED; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOSIS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881591945     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12312     Document Type: Article

References (33)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-215.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-29.
3. Tallant C, Marrero A, Gomis-Ruth FX. Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta 2010; 1803: 20-8.
4. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998; 18: 1163-72.
5. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50: 329-39.
6. Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007; 38: 748-52.
7. Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I, Penalba A, Molina CA, Montaner J. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005; 36: 1415-20.
8. Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, El-Zammar Z, Alam S, Hallenbeck JM, Kidwell CS, Warach S. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010; 41: e123-8.
9. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.
10. Castellanos M, Sobrino T, Millan M, Garcia M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Castillo J, Davalos A. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 2007; 38: 1855-9.
11. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20: 1681-9.
12. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-32.
13. Orbe J, Rodriguez JA, Calvayrac O, Rodriguez-Calvo R, Rodriguez C, Roncal C, Martinez de Lizarrondo S, Barrenetxe J, Reverter JC, Martinez-Gonzalez J, Paramo JA. Matrix metalloproteinase-10 is upregulated by thrombin in endothelial cells and increased in patients with enhanced thrombin generation. Arterioscler Thromb Vasc Biol 2009; 29: 2109-16.
14. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodriguez JA, Diez J, Libby P, Paramo JA. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006; 47: 1369-78.
15. de Lizarrondo SM, Roncal C, Calvayrac O, Rodriguez C, Varo N, Purroy A, Lorente L, Rodriguez JA, Doeuvre L, Hervas-Stubbs S, Angles-Cano E, Paramo JA, Martinez-Gonzalez J, Orbe J. Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. Arterioscler Thromb Vasc Biol 2012; 32: 1477-87.
16. Orbe J, Montero I, Rodriguez JA, Beloqui O, Roncal C, Paramo JA. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. J Thromb Haemost 2007; 5: 91-7.
17. Lorente L, Martin MM, Labarta L, Diaz C, Sole-Violan J, Blanquer J, Orbe J, Rodriguez JA, Jimenez A, Borreguero-Leon JM, Belmonte F, Medina JC, Lliminana MC, Ferrer-Aguero JM, Ferreres J, Mora ML, Lubillo S, Sanchez M, Barrios Y, Sierra A, et al. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care 2009; 13: R158.
18. Orbe J, Barrenetxe J, Rodriguez JA, Vivien D, Orset C, Parks WC, Birkland TP, Serrano R, Purroy A, Martinez de Lizarrondo S, Angles-Cano E, Paramo JA. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. Circulation 2011; 124: 2909-19.
19. Sobrino T, Millan M, Castellanos M, Blanco M, Brea D, Dorado L, Rodriguez-Gonzalez R, Rodriguez-Yanez M, Serena J, Leira R, Davalos A, Castillo J. Association of growth factors with arterial recanalization and clinical outcome in patients with ischemic stroke treated with tPA. J Thromb Haemost 2010; 8: 1567-74.
20. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis 2008; 25: 457-507.
21. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
22. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438-41.
23. Coll B, Rodriguez JA, Craver L, Orbe J, Martinez-Alonso M, Ortiz A, Diez J, Beloqui O, Borras M, Valdivielso JM, Fernandez E, Paramo JA. Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney Int 2010; 78: 1275-80.
24. Paramo JA, Beloqui O, Rodriguez JA, Diez J, Orbe J. Association between matrix metalloproteinase-10 concentration and smoking in individuals without cardiovascular disease. Rev Esp Cardiol 2008; 61: 1267-73.
25. Ning M, Wang X, Lo EH. Reperfusion injury after stroke: neurovascular proteases and the blood-brain barrier. Handb Clin Neurol 2009; 92: 117-36.
26. Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2011; 20: 47-54.
27. Jiang X, Namura S, Nagata I. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett 2001; 305: 41-4.
28. Ning M, Sarracino DA, Buonanno FS, Krastins B, Chou S, McMullin D, Wang X, Lopez M, Lo EH. Proteomic protease substrate profiling of tPA treatment in acute ischemic stroke patients: a step toward individualizing thrombolytic therapy at the bedside. Transl Stroke Res 2010; 1: 268-75.
29. Cuadrado E, Rosell A, Penalba A, Slevin M, Alvarez-Sabin J, Ortega-Aznar A, Montaner J. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J Proteome Res 2009; 8: 3191-7.
30. Morancho A, Rosell A, Garcia-Bonilla L, Montaner J. Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? Ann N Y Acad Sci 2010; 1207: 123-33.
31. Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Davalos A. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005; 36: 1921-6.
32. Moldes O, Sobrino T, Millan M, Castellanos M, Perez de la Ossa N, Leira R, Serena J, Vivancos J, Davalos A, Castillo J. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA. Stroke 2008; 39: 2006-10.
33. Watters O, O'Connor JJ. A role for tumor necrosis factor-alpha in ischemia and ischemic preconditioning. J Neuroinflammation 2011; 8: 87.